India Pharma Outlook Team | Thursday, 16 October 2025
Biocon Biologics Ltd. (BBL), a leading global biosimilars company and subsidiary of Biocon Ltd., announced today the extension of its strategic collaboration with Civica, Inc. to include a new medicines, Insulin Glargine, to improve patient access to affordable, high-quality insulin in the USA.
Under the multi-year agreement, Biocon Biologics will manufacture and supply Insulin Glargine to Civica to market and distribute in the USA with pool agreement existing approvals granted under its label by the FDA.
The medicine will be marketed under Civica’s label and trade dress, and in California, the CalRx brand will be included. Biocon Biologics will continue to develop and commercially dispense its Insulin Glargine-yfgn, which was approved by the FDA in 2021 as the first interchangeable biosimilar insulin in the USA.
Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: “Biocon Biologics is committed to expanding access to affordable, high-quality insulins in the U.S. and globally…This collaboration enables us to reach underserved populations through new channels in direct alignment with our mission.”
Ned McCoy, President and Chief Executive Officer, Civica, Inc., said: “We are pleased to expand our partnership with Biocon Biologics, which helps us achieve a significant milestone in our insulin initiative. Today’s announcement allows us to realize our goal of bringing insulin to people who need it at a transparent low price.”
The collaboration builds on the existing partnership where Biocon Biologics supplies Insulin Aspart drug substance to Civica for U.S. manufacturing. Together, both organizations aim to strengthen insulin affordability and availability, addressing the needs of over 38 million Americans living with diabetes.
